INVIVYD SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. - IVVD, ADGI
INVIVYD SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. - IVVD, ADGI
NEW ORLEANS, March 10, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 3, 2023 to file lead plaintiff applications in a securities class action lawsuit against Invivyd, Inc. (the "Company") (NasdaqGM: IVVD) f/k/a Adagio Therapeutics, Inc. ("Adagio") (NasdaqGM: ADGI), if they purchased the Company's shares between November 29, 2021 and December 14, 2021, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Massachusetts.
Get Help
Invivyd investors should visit us at or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
Invivyd and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 14, 2021, the Company (then named Adagio) disclosed that in vitro test results for ADG20, its lead product candidate against the COVID-19 Omicron variant, revealed that it was 300 times less effective at neutralizing Omicron than it was against the other variants, despite assuring investors of the efficacy against Omicron only a few weeks prior.
On this news, shares of Adagio plummeted nearly 80%, from $34.26 per share on December 13, 2021, to $7.26 per share when the market closed on December 14, 2021.
The case is Brill v. Invivyd, Inc., No. 23-cv-10254.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit .
SOURCE ClaimsFiler
新奥尔良，2023年3月10日/美通社/--免费股东信息服务公司ClaimsFeller提醒投资者，他们有2023年4月3日在针对Invivyd，Inc.(纳斯达克股票代码：IVVD)f/k/a Adagio Treateutics，Inc.(纳斯达克股票代码：ADGI)的证券集体诉讼中提出主要原告申请，前提是他们在2021年11月29日和2021年12月14日，包括(“上课时间”)。此操作在中挂起美国香港特区地方法院马萨诸塞州。
寻求帮助
Invivyd投资者应致电或拨打免费电话(844)367-9658访问我们。Kahn Swick&Foti，LLC的律师可以为您讨论法律选择。
关于这起诉讼
Invivyd及其某些高管被控在Class期间未能披露重要信息，违反了联邦证券法。
在……上面2021年12月14日，该公司(当时名为Adagio)披露，其针对新冠肺炎奥密克戎变体的主要候选产品ADG20的体外测试结果显示，它对奥密克戎的中和效果是对其他变体的300倍，尽管几周前还向投资者保证了它对奥密克戎的有效性。
受此消息影响，Adagio的股价暴跌近80%，34.26美元上的每股2021年12月13日，至7.26美元收盘时的每股收益2021年12月14日。
情况是这样的布里尔诉因维维德公司。，编号23-cv-10254。
关于ClaimsFeller
ClaimsFeller的使命只有一个：作为信息来源，帮助散户投资者从证券集体诉讼和解中追回他们数十亿美元的份额。在ClaimsFiler.com上，投资者可以：(1)免费注册，获得各种证券集体诉讼案件的信息和和解网站，以便他们可以及时提交自己的索赔；(2)上传他们的投资组合交易数据，以便获得有关他们可能有经济利益的相关证券案件的通知；以及(3)向Kahn Swick&Foti律师事务所提交查询，以进行免费的案件评估。
要了解有关ClaimsFeller的更多信息，请访问。
源声明文件管理器
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧